Abstract
INTRODUCTION
Latinos face increased Alzheimer’s disease (AD) risk but are underrepresented in studies of APOE genotype disclosure. We evaluated the psychological impacts of APOE disclosure in the Información de la Enfermedad de Alzheimer para Latinos (IDEAL) study, a randomized controlled trial among Latinos in New York City.
METHODS
Latino northern Manhattan residents without self-reported AD (mean age 52, 69% women, 49% college graduates) were randomized in the period August 2021 to July 2024 to receive AD risk estimates to age 85 incorporating APOE genotype, family history, and ethnicity (disclosure) or the same factors excluding APOE (non-disclosure). Bilingual genetic counselors delivered risk estimates to both groups, unmasked to randomization. Follow-up surveys were completed 6 weeks, 9 months, and 15 months after risk delivery. Primary outcomes were impact of genetic testing in AD (IGT-AD) and Impact of Event Scale-Revised (IES-R). Secondary outcomes were changes from baseline in depression, anxiety, and perceived AD threat. Analyses used intention-to-treat with multiple imputation.
RESULTS
Disclosure (N = 194) and non-disclosure (N = 180) groups did not differ on IGT-AD (mean disclosure−non-disclosure difference [MD] at 6 weeks: −1.5, p = 0.14; 9 months: −1.2, p = 0.35; 15 months: −2.0, p = 0.07), IES-R (MD at 6 weeks: 0.00, p = 0.98; 9 months: 0.01, p = 0.84; 15 months: 0.03, p = 0.64), or change in secondary outcomes. Occurrence of disclosure-related adverse events was similar in the disclosure (N = 2) and non-disclosure (N = 3) groups.
DISCUSSION
In this Latino cohort, APOE disclosure did not have clinically significant adverse psychological effects, addressing an important evidence gap.
TRIAL REGISTRATION
ClinicalTrials.gov NCT04471779.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: | September 9, 2026
Neuro-Dementia